From "Investor Update" released to the market on 24/6/2014 on Page 7 "ATC Overview":
"USA & EU regulatory authorities agree to shorter and simpler, less costly, final Phase 3 clinical trial with a rapid (14 days) end-point for approval"
AVX Price at posting:
1.6¢ Sentiment: Hold Disclosure: Held